1589 related articles for article (PubMed ID: 31424364)
21. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
Gao Y; Huang Y
J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
[TBL] [Abstract][Full Text] [Related]
22. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
23. Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer.
Wang X; Zhang H; Bai M; Ning T; Ge S; Deng T; Liu R; Zhang L; Ying G; Ba Y
Mol Ther; 2018 Mar; 26(3):774-783. PubMed ID: 29456019
[TBL] [Abstract][Full Text] [Related]
24. Exosomal microRNA-588 from M2 polarized macrophages contributes to cisplatin resistance of gastric cancer cells.
Cui HY; Rong JS; Chen J; Guo J; Zhu JQ; Ruan M; Zuo RR; Zhang SS; Qi JM; Zhang BH
World J Gastroenterol; 2021 Sep; 27(36):6079-6092. PubMed ID: 34629821
[TBL] [Abstract][Full Text] [Related]
25. Cancer-Derived Exosomal miR-651 as a Diagnostic Marker Restrains Cisplatin Resistance and Directly Targets ATG3 for Cervical Cancer.
Zhu X; Long L; Xiao H; He X
Dis Markers; 2021; 2021():1544784. PubMed ID: 34567283
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells.
Kia V; Paryan M; Mortazavi Y; Biglari A; Mohammadi-Yeganeh S
J Cell Biochem; 2019 Apr; 120(4):5666-5676. PubMed ID: 30335891
[TBL] [Abstract][Full Text] [Related]
27. Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
Jiang L; Zhang Y; Guo L; Liu C; Wang P; Ren W
BMC Cancer; 2021 Dec; 21(1):1290. PubMed ID: 34856955
[TBL] [Abstract][Full Text] [Related]
28. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28.
Chen B; Sang Y; Song X; Zhang D; Wang L; Zhao W; Liang Y; Zhang N; Yang Q
Theranostics; 2021; 11(8):3932-3947. PubMed ID: 33664871
[TBL] [Abstract][Full Text] [Related]
29. Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt/β-Catenin Signaling.
Jia Z; Zhu H; Sun H; Hua Y; Zhang G; Jiang J; Wang X
Cancer Manag Res; 2020; 12():8733-8744. PubMed ID: 33061571
[TBL] [Abstract][Full Text] [Related]
30. Exosomal release of microRNA-454 by breast cancer cells sustains biological properties of cancer stem cells via the PRRT2/Wnt axis in ovarian cancer.
Wang L; He M; Fu L; Jin Y
Life Sci; 2020 Sep; 257():118024. PubMed ID: 32598931
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis.
Wang J; Jia J; Zhou L
Neoplasma; 2020 Nov; 67(6):1279-1292. PubMed ID: 32787433
[TBL] [Abstract][Full Text] [Related]
32. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma.
Li J; Hu C; Chao H; Zhang Y; Li Y; Hou J; Huang L
J Cell Mol Med; 2021 Oct; 25(19):9183-9198. PubMed ID: 34469038
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6.
Ge X; Jiang Y; Hu X; Yu X
Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003
[TBL] [Abstract][Full Text] [Related]
34. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.
Chen WX; Liu XM; Lv MM; Chen L; Zhao JH; Zhong SL; Ji MH; Hu Q; Luo Z; Wu JZ; Tang JH
PLoS One; 2014; 9(4):e95240. PubMed ID: 24740415
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition.
Shao Q; Zhang P; Ma Y; Lu Z; Meng J; Li H; Wang X; Chen D; Zhang M; Han Y; Liu H; Ma S
Gene; 2018 Apr; 652():48-58. PubMed ID: 29427737
[TBL] [Abstract][Full Text] [Related]
36. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
[TBL] [Abstract][Full Text] [Related]
37. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp.
Shen JG; Xu SN; Yin LG
Gen Physiol Biophys; 2020 Sep; 39(5):481-489. PubMed ID: 33084601
[TBL] [Abstract][Full Text] [Related]
38. Depletion of circPDSS1 inhibits ITGA11 production to confer cisplatin sensitivity through miR-515-5p in gastric cancer.
Wang Y; Tang S; Li L; Sun C; Liu Y; Zhao Y
J Chemother; 2023 Oct; 35(6):514-526. PubMed ID: 36484486
[TBL] [Abstract][Full Text] [Related]
39. Long Noncoding RNA Plasmacytoma Variant Translocation 1 Regulates Cisplatin Resistance via miR-3619-5p/TBL1XR1 Axis in Gastric Cancer.
Wu C; Hu Y; Ning Y; Zhao A; Zhang G; Yan L
Cancer Biother Radiopharm; 2020 Dec; 35(10):741-752. PubMed ID: 32407172
[No Abstract] [Full Text] [Related]
40. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
